Dolutegravir/abacavir/lamivudine FDC — Competitive Intelligence Brief

Dolutegravir/abacavir/lamivudine FDC (Dolutegravir/abacavir/lamivudine FDC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (INSTI + NRTIs). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination (INSTI + NRTIs) HIV integrase, HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Dolutegravir/abacavir/lamivudine FDC (Dolutegravir/abacavir/lamivudine FDC) — ViiV Healthcare. This fixed-dose combination inhibits HIV integrase and reverse transcriptase to prevent viral replication and reduce viral load in HIV-infected patients.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dolutegravir/abacavir/lamivudine FDC TARGET	Dolutegravir/abacavir/lamivudine FDC	ViiV Healthcare	phase 3	Antiretroviral combination (INSTI + NRTIs)	HIV integrase, HIV reverse transcriptase
Raltegravir, tenofovir/emtricitabine	Raltegravir, tenofovir/emtricitabine	University of California, San Francisco	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill	Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill	Charlotte-Paige Rolle, MD	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
B/FTC/TAF	B/FTC/TAF	The University of Texas Health Science Center, Houston	marketed	Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
BIC/FTC/TAF	BIC/FTC/TAF	Prism Health North Texas	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
bictegravir/emtricitabine/tenofovir alafenamide	bictegravir/emtricitabine/tenofovir alafenamide	Midland Research Group, Inc.	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Switch to B/F/TAF	Switch to B/F/TAF	University of Nairobi	marketed	Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (INSTI + NRTIs) class)

1. University College Dublin · 1 drug in this class
2. ViiV Healthcare · 1 drug in this class